DOCSLIB.ORG

Pcf5 Palliative Care Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pcf5 Palliative Care Formulary PCF5 PALLIATIVE CARE FORMULARY Published by palliativedrugs.com Ltd. Palliativedrugs.com Ltd Hayward House Study Centre Nottingham University Hospitals NHS Trust, City Campus Nottingham NG5 1PB United Kingdom www.palliativedrugs.com # palliativedrugs.com Ltd 2014 The moral rights of the editors have been asserted. PCF4þ ePDF 2013 PCF4þ ePDF 2012 PCF4 2011, reprinted 2012 (twice), 2013 PCF3 2007, reprinted 2008, 2009 PCF2 2002, reprinted 2003 PCF1 1998 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission in writing of palliativedrugs.com Ltd or as expressly permitted by law, or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to [email protected] or by ordinary mail to the above address. British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library. ISBN 978-0-9552547-9-6 Typeset by OKS Prepress Services Private Ltd, Chennai, India Printed by Halstan Printing Group, Amersham, UK DISCLAIMER Every effort has been made to ensure the accuracy of this text, and that the best information available has been used. However, palliativedrugs.com Ltd neither represents nor guarantees that the practices described herein will, if followed, ensure safe and effective patient care. The recommendations contained in this book reflect the editors’ judgement regarding the state of general knowledge and practice in the field as of the date of publication. Information in a book of this type can never be all-inclusive, and therefore will not cover every eventuality. Thus, those who use this book must make their own determinations regarding specific safe and appropriate patient-care practices, taking into account the personnel, equipment, and practices available at the hospital or other facility at which they are located. Neither palliativedrugs.com Ltd nor the editors can be held responsible for any liability incurred as a consequence of the use or application of any of the contents of this book. Mention of specific product brands does not imply endorsement. Particularly when prescribing a drug for the first time, a doctor (or other independent prescriber) should study the contents of the manufacturer’s Summary of Product Characteristics (SPC), paying particular attention to indications, contra-indications, cautions, drug interactions, and undesirable effects. PCF5 iii EDITORIAL STAFF Editors-in-Chief Robert Twycross DM, FRCP Emeritus Clinical Reader in Palliative Medicine, Oxford University Andrew Wilcock DM, FRCP Macmillan Clinical Reader in Palliative Medicine and Medical Oncology, Nottingham University Consultant Physician, Hayward House, Nottingham University Hospitals NHS Trust, City Campus Paul Howard BMedSci, MRCP Consultant in Palliative Medicine, Earl Mountbatten House, Isle of Wight NHS Trust Senior Editor Sarah Charlesworth BPharm, DipClinPharm, MRPharmS Specialist Pharmacist, Palliative Care Information and Website Management, Hayward House, Nottingham University Hospitals NHS Trust, City Campus Editor Claire Stark Toller MA, MA, MRCP Locum Consultant in Palliative Medicine, Macmillan Unit, Royal Bournemouth and Christchurch Hospitals NHS Trust Associate Editor Julie Mortimer BPharm, MRPharmS Malcolm Mortimer Media, Nottingham (former Senior Editor) Editorial Board Andrew Broadbent BMedSc, MHM, FRACP, FAChPM Hammondcare Director of Palliative Care, Northern Sydney, Head of Palliative Care Royal North Shore Hospital, Senior Lecturer University of Sydney, NSW, Australia Rachel Burman MA, FRCP Consultant in Palliative Care, King’s College Hospital NHS Foundation Trust, Cicely Saunders Institute, London, UK Venkata Chaitanya MRCP Consultant in Palliative Medicine, Derby Hospitals NHS Trust, Derby, UK Alpna Chauhan MRCP Consultant in Palliative Medicine, John Eastwood Hospice, Sutton-in-Ashfield, Nottinghamshire, UK Brian Creedon MMedSci, MRCPI Consultant in Palliative Medicine, Waterford Regional Hospital, Waterford, Ireland Vincent Crosby FRCP Consultant in Palliative Medicine, Hayward House Specialist Palliative Care Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK iv www.palliativedrugs.com EDITORIAL STAFF Andrew Davies MSc, MD, FRCP Consultant in Palliative Medicine, St. Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, UK Joanne Droney, PhD, MRCPI Consultant in Palliative Medicine, Royal Marsden Hospital, London, UK Jo Elverson MA(Ed) MRCP Consultant in Palliative Medicine, Helen and Douglas House Hospices for Children & Young Adults, Oxford, UK Ruth England MRCP Consultant in Palliative Medicine, Derby Hospitals NHS Trust, Derby, UK Marie Fallon MD, FRCP St Columbas Hospice Chair of Palliative Medicine, University of Edinburgh and Edinburgh Cancer Centre, UK. Jeff Fry BSc, PhD Associate Professor and Reader in Molecular Toxicology, School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, UK Catherine Gwilt BSc, MRCP Specialist Registrar in Palliative Medicine, KSS Palliative Medicine rotation, London, UK Vanessa Halliday PhD, RD Lecturer in Public Health, School of Health and Related Research, University of Sheffield, UK Janet Hardy BSc, MD, FRACP Director, Department of Palliative and Supportive Care, Mater Health Services, Brisbane; Professor of Palliative Medicine, University of Queensland, Australia Miriam Johnson MD, FRCP, MRCP Professor of Palliative Medicine, Hull York Medical School, University of Hull, Hull, UK Paul Keeley FRCP Consultant in Palliative Medicine, Glasgow Royal Infirmary, Glasgow, Scotland, UK. Vaughan Keeley PhD, FRCP Consultant in Palliative Medicine, Derby Hospitals NHS Trust, Derby, UK Samuel King MRCP Palliative Medicine Consultant, St Elizabeth Hospice and Ipswich Hospital Trust, Ipswich, Suffolk, UK Malgorzata Krajnik MD, PhD Head of Palliative Care Department, Nicolaus Copernicus University, L Rydygier Collegium Medicum, Bydgoszcz, Poland; Consultant in Palliative Medicine, University Hospital No 1, Bydgoszcz, Poland Susie Lapwood MA, MRCGP, DFSRH, DipPallMed Head of Research, Education and Professional Development and Senior Specialty Doctor, Helen and Douglas House Hospices for Children and Young Adults, Oxford UK Mark Lee MD, MRCP Consultant in Palliative Care, St Benedict’s Hospice and Specialist Palliative Care Centre, Sunderland, UK Vivian Lucas MA, MRCGP, DA, DRCOG Medical Director, Garden House Hospice, Letchworth Garden City, UK Michael Lucey MB, BMedSci, FRCPI Consultant in Palliative Medicine, Milford Hospice, Limerick and HSE mid West, Ireland PCF5 v EDITORIAL STAFF Staffan Lundstrom MD, PhD Department of Palliative Medicine, Stockholms Sjukhem Foundation and Karolinska Institute, Stockholm, Sweden Tim Morgan BSc, FRCP, FRCS Macmillan Consultant and Lead Physician in Palliative Medicine, Roxburghe House and Aberdeen Royal Infirmary, NHS Grampian and Honorary Senior Lecturer, Aberdeen University, UK Simon Noble MD, FRCP, Dip Pall Med Clinical Reader in Palliative Medicine, Cardiff University, UK Victor Pace FRCP, FRCS, DipPallMed Consultant in Palliative Medicine, St Christopher’s Hospice, London, UK Rachel Quibell MRCGP, FRCP Consultant in Palliative Medicine, Newcastle upon Tyne Hospitals FT and Marie Curie Hospice, Newcastle, UK Joy Ross PhD, MRCP Consultant in Palliative Medicine, Royal Marsden Hospital, London, UK John Shaw PhD Hayward House Study Centre, Nottingham University Hospitals NHS Trust, City Campus, Nottingham, UK Anna Spathis MA, MSc, MRCP, MRCGP, FHEA Consultant in Palliative Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK Mark Taubert MRCGP, MSc, DipPallMed Consultant in Palliative Medicine, Holme Tower Marie Curie Centre, Penarth, UK Jillian Wall MRCP Registrar in Palliative medicine, Hayward House Specialist Palliative Care Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK Rebecca White BSc, MSc, MRPharmS (IPresc), FFRPS Consultant Pharmacist: Nutrition & Intestinal Failure, Oxford University Hospitals NHS Trust, Oxford, UK Zbigniew Zylicz MD, PhD Consultant in Palliative Medicine, Hildegard Hospiz, Basel, Switzerland vi www.palliativedrugs.com CONTENTS Preface xi Summary of main changes in PCF5 xii How PCF is constructed xiii Getting the most out of PCF xv The use of drugs beyond (off-label) and without marketing authorization xix Drug names xxv Abbreviations xxvii Part 1 Drug Monographs 1 Gastro-intestinal system 1 Antacids 1 Antimuscarinics 5 Prokinetics 22 H2-receptor antagonists 26 Misoprostol 29 Proton pump inhibitors 31 Loperamide 37 Laxatives 40 Products for haemorrhoids 59 Pancreatin 60 2 Cardiovascular system 63 Furosemide 63 Spironolactone 68 Systemic local anaesthetics 71 *Clonidine 76 Glyceryltrinitrate 79 Nifedipine 83 Anticoagulants 86 Haemostatics 98 3 Respiratorysystem 105 Bronchodilators 105 InhaledCORTICOSTEROIDS 1 Oxygen 129 Drugsforcough 138 PCF5 vii CONTENTS 4 Central nervous system 147 Psychotropics 147 Benzodiazepines 148 Melatonin 165 Antipsychotics 168 Antidepressants 190 *Psychostimulants 224 *Cannabinoids 229 Anti-emetics 235 Anti-epileptics 254 5 Analgesics 291 Principles of use of analgesics 291 Adjuvant analgesics 295 Paracetamol 299 Nefopam 305 Non-steroidal anti-inflammatory drugs (NSAIDs) 307 Weak opioids 346 Strong opioids 357 Opioid antagonists 450 6 Infections 461 Antibacterials in palliative care 461
Load more

Recommended publications
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Innovation in Pain Management
    INNOVATION IN PAIN MANAGEMENT The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 12 December 2002 Edited by L A Reynolds and E M Tansey Volume 21 2004 ©The Trustee of the Wellcome Trust, London, 2004 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2004 The Wellcome Trust Centre for the History of Medicine at University College London is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 85484 097 7 Histmed logo images courtesy Wellcome Library, London. Design and production: Julie Wood at Shift Key Design 020 7241 3704 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2004) Innovation in Pain Management. Wellcome Witnesses to Twentieth Century Medicine, vol. 21. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Witness Seminars: Meetings and publications;Acknowledgements vii E M Tansey and L A Reynolds Introduction Christina Faull xix Transcript Edited by L A Reynolds and E M Tansey 1 Appendix 1 73 Extract from an annotated Physiological Society interview with Patrick Wall (1925–2001) by Martin Rosenberg and Steve McMahon (5 February 1999) Appendix 2 83 Morphine: Optimal potential for benefit with a minimum risk of adverse events and burden by Jan Stjernswärd (12 April 2004) References 85 Biographical notes 103 Index 115 Key to cover photographs ILLUSTRATIONS AND CREDITS Figure 1 Dr Cicely Saunders and two patients at St Joseph’s on their golden wedding anniversary, 1960.
    [Show full text]
  • Pain Management 101
    PAIN MANAGEMENT 101 By: Vicki McCulloch RN, NP & DeAnna Looper RN, CHPN, CHPCA Expect more from us. We do. Objectives • Identify a step-wise approach to pain management. • Identify the WHO Pain Ladder. • Identify non-pharmacological pain control measures. • Identify adjuvant treatment measures. • Identify common myths and truths • Identify common side effects and treatment options. Expect more from us. We do. Pain Management Principles • Use Multi-Treatment and Multi-Discipline Approach • Combine opioids with non-opioid medications • Non-pharmaceutical approaches • Include family and caregiver in planning • Include the patient! • Coordinate with facility • Coordinate with all providers- • Primary Care Provider • Nursing Home Physician • Hospice IDG Members Expect more from us. We do. Utilize the WHO Ladder World Health Organization • (WHO) “analgesic ladder” • Follow the steps as indicated. • Determine if adjuvants are necessary. Expect more from us. We do. WHO Pain Ladder STEP 3 “Strong” opioid for severe pain +/- non-opioid +/- adjuvant STEP 2 “Mild” opioid for mild- moderate pain +/- non- opioid +/- adjuvant STEP 1 Non-opioid + / - adjuvant Expect more from us. We do. Step 1-Mild Pain NON-OPIOID MEDICATION OPTIONS • Acetaminophen (Tylenol)-(Paracetamol)-(Panadol) • Non-steroidal anti-inflammatory drugs (NSAIDs) Traditional NSAIDS Ibuprofen-(Motrin) Aspirin-(Bayer) Naproxen- (Aleve) Nabumetone-(Relafen) Cox-2 Inhibitors Celecoxib-(Celebrex) Rofecoxib-(Vioxx) Valdecoxib-(Bextra) Expect more from us. We do. Adjuvants • Antidepressants
    [Show full text]
  • Journal Official Journal of the World Medical Association, Inc
    ISSN 2256-0580 COVID-19 World Medical Journal Official Journal of The World Medical Association, Inc. Nr. 2, April 2020 vol. 66 Contents Editorial . 1 COVID-19: the Asian Perspective . 2 The Corona Virus Outbreak on South African Medical Schemes . 13 Reform Proceeding of Organ Donation and Transplantation System in China . 15 The Impact of Climate Change on Health . 19 Physical Activities of Doctors in Rivers State, Southern Nigeria . 21 Palliative Care: What, Who, When, How? . 25 The “Normalization” of Euthanasia in Canada: the Cautionary Tale Continues . 28 Appeal for Policy Promotion . 38 This Month Consider Indoor Air Health . 40 Singapore Medical Association – sixty years on . iii World Medical Association Officers, Chairpersons and Officials Dr . Miguel Roberto JORGE Dr . David Barbe Dr . Leonid EIDELMAN Prof . Dr . Frank Ulrich WMA President, WMA President-Elect, WMA Immediate Past-President MONTGOMERY Brazilian Medical Association American Medical Association Israeli Medical Association Chairperson of Council Rua-Sao Carlos do Pinhal 324, AMA Plaza, 330 N. Wabash, Suite 2 Twin Towers, 35 Jabotinsky St., Bundesärztekammer CEP-01333-903 Sao Paulo-SP 39300 P.O. Box 3566 Herbert-Lewin-Platz 1 (Wegelystrasse) Brazil 60611-5885 Chicago, Illinois 52136 Ramat-Gan 10623 Berlin United States Israel Germany Dr . Otmar KLOIBER Dr . Mari MICHINAGA Dr . Ravindra Sitaram Dr . Andreas RUDKJØBING Secretary General WMA Vice-Chairperson of Council WANKHEDKAR WMA Chairperson of the Medical World Medical Association Japan Medical Association WMA Treasurer Ethics Committee 13 chemin du Levant 2-28-16 Honkomagome Indian Medical Association Danish Medical Association 01212 Ferney-Voltaire 113-8621 Bunkyo-ku, Tokyo Indraprastha Marg Kristianiagade 12 France Japan 110 002 New Delhi 2100 Copenhagen 0 India Denmark Dr .
    [Show full text]
  • Department of Health
    DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.
    [Show full text]
  • Composition Colicon ® Tablet: Each Tablet Contains Dicycloverine Hydrochloride BP 10 Mg
    Composition Colicon ® Tablet: Each tablet contains Dicycloverine Hydrochloride BP 10 mg. Colicon ® Syrup: Each 5 ml syrup contains Dicycloverine Hydrochloride BP 10 mg. Colicon ® Injection: Each 2 ml ampoule contains Dicycloverine Hydrochloride BP 20 mg. Description Colicon ® (Dicycloverine Hydrochloride) is an antispasmodic and anticholinergic (antimuscarinic) agent. Colicon ® relieves smooth muscle spasm of the gastrointestinal tract, urinary bladder & ureter. It works at specific receptors, called cholinergic (or muscarinic) receptors, located on the involuntary muscle in the walls of the gut. As antispasmodic drug Colicon ® causes the gut muscle to relax, relieving the pain of colic produced by gut muscle contraction and spasm. Also it has direct musculotropic action. Indication and usage Irritable bowel syndrome (Diarrhea Predominant) Infantile colic GIT spasm Diverticulitis Abdominal colic Diarrhea Dysentery Dosage and administration Adults : 10 to 20 mg three to four times a day. Maximum recommended oral dose is 160 mg daily in divided dose. Children : Children over 6 months of age- 5 to 10 mg three times a day. IM injection: Usual recommended injectable dose is 80 mg daily by IM route in 4 divided dose. Side-Effects Insomnia, headache, weakness, confusion, increased ocular tension, urinary hesitancy, palpitations etc. Precaution Use with caution in patients with autonomic neuropathy, hepatic or renal disease, ulcerative colitis, coronary heart disease, congestive heart failure, cardiac tachyarrhythmia, known or suspected prostatic hypertrophy. Contraindication Obstructive uropathy Obstruction disorder in GIT Severe ulcerative colitis Unstable cardiovascular status in acute hemorrhage Glucoma Myasthenia gravis Patients with hypersensitivity to dicycloverine hydrochloride Infants less than 6 months of age Use in Pregnancy and Lactation Pregnancy Category B.
    [Show full text]
  • 1. What Panadol Night Does 2. Check Before You Take Panadol Night
    GSK LOCisresponsibletoapprovethechangedocumentation, artworkbrief and finalartwork,ensuringthatitisaccurate,consistent complete. GSK MarketisresponsibletoadviseSDCwhenchanges GSK SDCisresponsibleforsitetechnicalrequirements Storage conditions andShelfLife Formulation, Tablet embossing, Formulation, Tablet IMPORTANT required impactthefollowing: and pre-presssuitability. Local approversmustensurethattrademarkand NOTE TO MARKET NOTE TO copyright statementsincludedinthebrief comply withguidanceprovidedby Legal: Global Trade Marks. Legal: GlobalTrade PATIENT INFORMATION LEAFLET 2. Check before you take Panadol Night Do not take Panadol Night: • if you have ever had an allergic reaction to paracetamol, diphenhydramine hydrochloride or to any of the other ingredients (listed in Section 6) • if you have porphyria (too much of the pigment called porphyrin which may discolour the urine) • if you have taken another medicine containing paracetamol in the last 4 hours. Contains paracetamol. Do not take with any other antihistamine-containing products, including those used Night on your skin or in cough and cold medicines. Paracetamol + Diphenhydramine Ask your doctor before you take this medicine: Please read right through this leaflet before you start using this medicine. • if you have liver or kidney problems, including alcoholic liver disease, are This medicine is available without prescription, but you still need to use underweight or malnourished or regularly drink alcohol. You may need to avoid Panadol Night carefully to get the best results from them. using this product altogether or limit the amount of paracetamol that you take. • Keep this leaflet you may need to read it again. • if you have epilepsy, or seizure disorders • If you have any questions, or if there is anything you do not understand, • if you have an obstruction in your stomach or gut (for example, because of an ulcer) ask your pharmacist.
    [Show full text]
  • Drug Tariff Price Changes
    Drug tariff September 2018 Top 10 price reductions since August 2018 Medicine Pack size Basic price August 2018 Difference Pergolide 1mg tablets 100 tablet £116.86 £131.66 -£14.80 Ropinirole 5mg tablets 84 tablet £170.16 £175.32 -£5.16 Olanzapine 20mg orodispersible tablets sugar free 28 tablet £57.20 £62.20 -£5.00 Naproxen 250mg/5ml oral suspension 100 ml £48.75 £52.50 -£3.75 Telmisartan 80mg / Hydrochlorothiazide 25mg tablets 28 tablet £14.98 £17.00 -£2.02 Yellow soft paraffin solid 500 gram £6.24 £8.02 -£1.78 Cefadroxil 500mg capsules 20 capsule £5.87 £7.61 -£1.74 Etoricoxib 120mg tablets 28 tablet £17.03 £18.59 -£1.56 Gabapentin 800mg tablets 100 tablet £24.86 £25.50 -£0.64 Felodipine 2.5mg modified-release tablets 28 tablet £5.68 £6.31 -£0.63 Top 10 price increases since August 2018 Medicine Pack size Basic price August 2018 Difference Anagrelide 500microgram capsules 100 capsule £378.98 £350.70 £28.28 Macrogol 3350 oral powder 8.5g sachets sugar free 28 sachet £29.85 £3.89 £25.96 Linezolid 600mg tablets 10 tablet £305.44 £283.32 £22.12 Famciclovir 125mg tablets 10 tablet £53.45 £36.72 £16.73 Sevelamer 2.4g oral powder sachets sugar free 60 sachet £214.65 £198.78 £15.87 Diamorphine 500mg powder for solution for injection ampoules 5 ampoule £199.00 £187.70 £11.30 Dicycloverine 20mg tablets 84 tablet £269.84 £259.39 £10.45 Meloxicam 15mg orodispersible tablets sugar free 30 tablet £25.50 £15.50 £10.00 Meloxicam 7.5mg orodispersible tablets sugar free 30 tablet £25.50 £15.50 £10.00 Dicycloverine 10mg tablets 100 tablet £252.78 £242.99
    [Show full text]
  • Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
    IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 1/89 PROTOCOL TITLE: EFFICACY OF DIOSMECTITE (SMECTA®) IN THE SYMPTOMATIC TREATMENT OF ACUTE DIARRHOEA IN ADULTS. A MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY STUDY PROTOCOL STUDY number: F-FR-00250-105 (Diosmectite- BN 00250) EudraCT number: n° 2015-001138-10 Final Version (with Amendment No. 4): 07 January 2019 Sponsor’s Medically Responsible Person: Study Sponsor: PPD Ipsen Pharma SAS PPD 65 quai Georges Gorse Ipsen Pharma SAS 92100 Boulogne-Billancourt, France 65 quai Georges Gorse Tel: PPD 92100 Boulogne-Billancourt, France Fax: PPD Tel: PPD Fax: PPD Monitoring Office: and/or CRO Co-ordinating Investigator: PPD PPD PPD Délégation à la Recherche Ipsen Pharma SAS Centre Hospitalier Régional Universitaire 65 quai Georges Gorse de Lille 92100 Boulogne-Billancourt, France 2, avenue Oscar Lambret, Tel: PPD 59037 Lille, France Cedex Fax: PPD Tel: PPD Fax: PPD Pharmacovigilance/Emergency Contact: PPD Ipsen Innovation, ZI de Courtaboeuf - 5 avenue du Canada - 91940 Les Ulis - France Tel: PPD Tel: PPD – PPD For SAEs reporting: Fax: PPD Email: PPD Persons supplied with this information must understand that it is strictly confidential. Information contained herein cannot be disclosed, submitted for publication or used for any purpose other than that contemplated herein without the sponsor’s prior written authorisation. IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 2/89 INVESTIGATOR’S AGREEMENT Investigator Agreement and Signature: I have read and agree to Protocol F-FR-00250-105 entitled Efficacy of the diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults.
    [Show full text]
  • Multi-Discipline Review/Summary, Clinical, Non-Clinical
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210868Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA Multi-disciplinary Review and Evaluation NDA 210868 Lorlatinib NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) 210868 Priority or Standard Priority Submit Date(s) December 5, 2017 Received Date(s) December 5, 2017 PDUFA Goal Date November 5, 2018 Division/Office OHOP/DOP2 Review Completion Date November 2, 2018 Established Name Lorlatinib (Proposed) Trade Name LORBRENA Pharmacologic Class Kinase inhibitor Code name PF-06463922 Applicant Pfizer, Inc. Formulation(s) 100 mg and 25 mg tablets Dosing Regimen 100 mg orally once daily Applicant Proposed For the treatment of patients with anaplastic lymphoma kinase Indication(s)/Population(s) (ALK)-positive metastatic non-small cell lung cancer (NSCLC) previously treated with one or more ALK tyrosine kinase inhibitors (TKIs). Recommendation on Accelerated Approval Regulatory Action Recommended For the treatment of patients with anaplastic lymphoma kinase Indication(s)/Population(s) (ALK)-positive metastatic non-small celling cancer (NSCLC) (if applicable) whose disease has progressed on: • crizotinib and at least one other ALK inhibitor for metastatic disease; or • alectinib as the first ALK inhibitor therapy for metastatic disease; or • ceritinib as the first ALK inhibitor therapy for metastatic disease 1 Version date: February 1, 2016 for initial rollout (NME/original BLA reviews) Reference ID: 4344794 NDA Multi-disciplinary Review and Evaluation NDA 210868 Lorlatinib Table of Contents Reviewers of Multi-Disciplinary Review and Evaluation .............................................................. 13 Additional Reviewers of Application ............................................................................................
    [Show full text]
  • Ebook Download Cicely Saunders: the Founder of the Modern
    CICELY SAUNDERS: THE FOUNDER OF THE MODERN HOSPICE MOVEMENT PDF, EPUB, EBOOK Shirley Du Boulay, Marianne Rankin | 320 pages | 01 Sep 2007 | SPCK Publishing | 9780281058891 | English | London, United Kingdom Remembering Dame Cicely Saunders: Founder of Hospice Nursing Times. As a building can allow one to shelter in space, it can also allow one to shelter in time. For Saunders, the importance of St. In the brochure, a specific section is dedicated to emphasising the modern scientific medicine that will be practiced, and improved, at St. As outlined in The Need , research into pain and other symptoms specific to the terminally ill was to be an important aspect of the work conducted at St. To this end, Saunders specifically incorporated a post-mortem room and wrote to the Borough Coroner to ascertain any special requirements he might have. By including this room, Cicely provided the space to conduct evidence-based research — important for a fledgling medical field to gain acceptance and authority in its treatments from medical colleagues and others. These studies showed that pain described by patients could be due to more than just the primary cancer — in contrast to what was widely believed — and that pain control should be based on careful assessment of pain to identify the most appropriate medical treatment, be it further surgery or medication. Robert Twycross [38] who conducted clinical research into pain at St. The Hospice provided a ready subset of patients for clinical trials, whilst the high standards of the purpose-built facility— matching those of the National Health Service — arguably added credence to any data that was published from the Hospice.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]